Aptiom

June 30, 2017June 30, 2017

Zebinix/Aptiom Does Not Reduce Cognition in Epileptic Children, Phase 2 Clinical Trial Indicates

News

The epilepsy therapy known as Zebinix in Europe and Aptiom in the United States does not impair cognition in children, a Phase 2 clinical trial indicates. Children with focal epilepsy who ... Read more

May 18, 2016

Bial’s Submission for Once-daily Epilepsy Treatment Zebinix Accepted by EMA

News

Bial has announced that the European Medicines Agency (EMA) will review recent clinical trial data for Zebinix (eslicarbazepine acetate) as a once-daily treatment for patients suffering from newly diagnosed epilepsy. The results of ... Read more